Jeremy R. Graff

18.6k total citations · 5 hit papers
84 papers, 14.7k citations indexed

About

Jeremy R. Graff is a scholar working on Molecular Biology, Oncology and Biotechnology. According to data from OpenAlex, Jeremy R. Graff has authored 84 papers receiving a total of 14.7k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Molecular Biology, 21 papers in Oncology and 17 papers in Biotechnology. Recurrent topics in Jeremy R. Graff's work include PI3K/AKT/mTOR signaling in cancer (15 papers), Cancer Research and Treatments (15 papers) and Cancer-related gene regulation (12 papers). Jeremy R. Graff is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (15 papers), Cancer Research and Treatments (15 papers) and Cancer-related gene regulation (12 papers). Jeremy R. Graff collaborates with scholars based in United States, Canada and Singapore. Jeremy R. Graff's co-authors include James G. Herman, Sanna Myöhänen, B D Nelkin, S B Baylin, Jean‐Pierre J. Issa, Paula M. Vertino, Stephen B. Baylin, Arrigo De Benedetti, Bruce W. Konicek and Julia H. Carter and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Jeremy R. Graff

84 papers receiving 14.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

1996 4.8k citations James G. Herman, Jeremy R. Graff et al. profile →
Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia

1997 1.6k citations James G. Herman, Jeremy R. Graff et al. Advances in cancer research profile →
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma

1998 1.5k citations James G. Herman, Jeremy R. Graff et al. profile →
E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas.

1995 668 citations Jeremy R. Graff, James G. Herman et al. PubMed profile →
eIF-4E expression and its role in malignancies and metastases

2004 600 citations Arrigo De Benedetti, Jeremy R. Graff profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeremy R. Graff United States	38	12.0k	3.2k	2.6k	2.2k	1.6k	84	14.7k
Alfonso Bellacosa United States	52	10.8k 0.9×	4.0k 1.3×	2.3k 0.9×	2.0k 0.9×	1.1k 0.7×	118	14.4k
Minoru Toyota Japan	55	9.5k 0.8×	3.4k 1.1×	2.9k 1.1×	2.7k 1.2×	1.2k 0.7×	134	12.5k
Jürgen Behrens Germany	58	15.5k 1.3×	3.8k 1.2×	1.7k 0.7×	1.5k 0.7×	1.4k 0.9×	113	19.3k
Leif W. Ellisen United States	54	9.4k 0.8×	4.9k 1.6×	3.9k 1.5×	1.1k 0.5×	2.1k 1.3×	152	15.9k
Reinhard Buettner Germany	60	8.9k 0.7×	3.4k 1.1×	2.1k 0.8×	1.2k 0.6×	1.6k 1.0×	312	14.3k
Takashi Tokino Japan	62	12.8k 1.1×	6.5k 2.1×	3.8k 1.5×	1.7k 0.8×	1.7k 1.0×	227	17.4k
Samuel C. Mok United States	67	7.7k 0.6×	3.5k 1.1×	3.7k 1.4×	1.2k 0.6×	1.6k 1.0×	243	14.2k
Michael A. Tainsky United States	47	7.8k 0.7×	5.2k 1.7×	2.5k 1.0×	1.1k 0.5×	1.9k 1.2×	156	12.5k
Jiřina Bártková Denmark	62	10.5k 0.9×	7.8k 2.5×	2.8k 1.1×	1.3k 0.6×	1.8k 1.1×	136	15.4k
Paul Polakis United States	64	17.8k 1.5×	4.9k 1.6×	1.6k 0.6×	2.6k 1.2×	1.8k 1.1×	118	21.9k

Countries citing papers authored by Jeremy R. Graff

Since Specialization

Citations

This map shows the geographic impact of Jeremy R. Graff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeremy R. Graff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeremy R. Graff more than expected).

Fields of papers citing papers by Jeremy R. Graff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeremy R. Graff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeremy R. Graff. The network helps show where Jeremy R. Graff may publish in the future.

Co-authorship network of co-authors of Jeremy R. Graff

This figure shows the co-authorship network connecting the top 25 collaborators of Jeremy R. Graff. A scholar is included among the top collaborators of Jeremy R. Graff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeremy R. Graff. Jeremy R. Graff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chan, Anissa, Nandita Bose, Nandita Bose, et al.. (2020). P862 Clinical benefit potentially evident with immunopharmacodynamic responses in prior-checkpoint failed metastatic melanoma patients treated with imprime PGG and pembrolizumab. Poster presentations. A10.1–A10. 2 indexed citations

Bose, Nandita, Keith Gorden, Anissa Chan, et al.. (2017). Abstract B29: Innate immune modulation: The novel immunotherapeutic Imprime PGG triggers the anti-cancer immunity cycle in concert with tumor-targeting, anti-angiogenic and checkpoint inhibitor antibodies. Cancer Immunology Research. 5(3_Supplement). B29–B29. 2 indexed citations

Fraser, Kathryn, Anissa Chan, Ross B. Fulton, et al.. (2016). Abstract 2335: Imprime PGG triggers PD-L1 expression on tumor and myeloid cells and prevents tumor establishment in combination with αPD-L1 treatment in vivo. Cancer Research. 76(14_Supplement). 2335–2335. 6 indexed citations

Qiu, Xiaohong, et al.. (2016). Imprime PGG, a yeast β-glucan PAMP elicits a coordinated immune response in combination with anti-PD1 antibody. The Journal of Immunology. 196(1_Supplement). 214.16–214.16. 4 indexed citations

Leonardo, Steven, et al.. (2016). Abstract A160: Imprime PGG binds to neutrophils through complement, Fc, and dectin-1 receptors, priming these cells for enhanced ROS production and tumor cell cytotoxicity. Cancer Immunology Research. 4(1_Supplement). A160–A160. 5 indexed citations

Fraser, Kathryn, et al.. (2016). Abstract A128: Imprime PGG, a novel, clinical-stage pathogen associated molecular pattern, modulates MDSC function, facilitating a coordinated antitumor immune response. Cancer Immunology Research. 4(11_Supplement). A128–A128. 1 indexed citations

Fraser, Kathryn, et al.. (2015). Abstract A3: Imprime PGG triggers a coordinated anti-cancer immune response in concert with anti-angiogenic antibodies, re-polarizing the immune microenvironment to suppress tumor growth. Molecular Cancer Therapeutics. 14(12_Supplement_2). A3–A3. 1 indexed citations

Gkogkas, Christos G., Arkady Khoutorsky, Ruifeng Cao, et al.. (2014). Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-like Phenotypes. Cell Reports. 9(5). 1742–1755. 151 indexed citations

Graff, Jeremy R., Bruce W. Konicek, Rebecca L. Lynch, et al.. (2009). eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival. Cancer Research. 69(9). 3866–3873. 156 indexed citations

10.

Graff, Jeremy R., Bruce W. Konicek, Julia H. Carter, & Eric G. Marcusson. (2008). Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy. Cancer Research. 68(3). 631–634. 264 indexed citations

11.

Markey, Michael, Jeremy R. Graff, Julia H. Carter, & Taiping Chen. (2006). Alternative Splicing of a Cancer-Associated Intronic Variant of TG-FBR1 in Cancer Cell Lines. Cancer Research. 66. 586–586. 1 indexed citations

12.

Graff, Jeremy R.. (2002). Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma. Expert Opinion on Therapeutic Targets. 6(1). 103–113. 54 indexed citations

13.

Graff, Jeremy R., James A. Deddens, Bruce W. Konicek, et al.. (2001). Integrin-linked kinase expression increases with prostate tumor grade.. PubMed. 7(7). 1987–91. 115 indexed citations

14.

Zinda, Michael, Mac Johnson, Candice L. Horn, et al.. (2001). AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon.. PubMed. 7(8). 2475–9. 132 indexed citations

15.

Zimmer, S G, et al.. (2000). Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis.. PubMed. 20(3A). 1343–51. 136 indexed citations

16.

Kuerbitz, Steven J., et al.. (1999). Deletion of p16INK4A/CDKN2 and p15INK4B in human somatic cell hybrids and hybrid-derived tumors.. PubMed. 10(1). 27–33. 6 indexed citations

17.

Narayan, Ajita, Weizhen Ji, Aizen J. Marrogi, et al.. (1998). Hypomethylation of pericentromeric DNA in breast adenocarcinomas. International Journal of Cancer. 77(6). 833–838. 195 indexed citations

18.

Graff, Jeremy R., Arrigo De Benedetti, Jack W. Olson, et al.. (1997). Translation of ODC mRNA and Polyamine Transport Are Suppressed inras-Transformed CREF Cells by Depleting Translation Initiation Factor 4E. Biochemical and Biophysical Research Communications. 240(1). 15–20. 38 indexed citations

19.

Herman, James G., et al.. (1997). Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia. Advances in cancer research. 72. 141–196. 1640 indexed citations breakdown →

20.

Rinker‐Schaeffer, Carrie, Jeremy R. Graff, Arrigo De Benedetti, Stephen G. Zimmer, & Robert E. Rhoads. (1993). Decreasing the level of translation initiation factor 4E with antisense rna causes reversal of ras‐mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. International Journal of Cancer. 55(5). 841–847. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact